AMG 102 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Summary
RATIONALE: Monoclonal antibodies, such as AMG 102, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.
PURPOSE: This phase II trial is studying how well AMG 102 works in treating patients with persistent or recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.
Description
OBJECTIVES:
Primary
- To estimate the 6-month progression-free survival (PFS) rate in patients with persistent or recurrent ovarian epithelial, fallopian tube, or primary peritoneal carcinoma treated with fully human anti-HGF monoclonal antibody AMG 102.
- To estimate the objective tumor response (complete or partial response) rate in patients treated with this drug.
Secondary
- To determine the frequency and severity of adverse events associated with this drug in these patients.
- To determine the duration of PFS and overall survival of patients treated with this drug.
Tertiary
- To explore the association between a panel of biomarkers (as assayed by IHC and mutation analysis) and measures of response to treatment and clinical outcome in archived tumor tissue. (Translational)
- To evaluate circulating pre- and post-treatment levels of hepatocyte growth factor/scatter factor and markers of angiogenesis, and their association with response to treatment and clinical outcome. (Translational)
OUTLINE: This is a multicenter study.
Patients receive fully human anti-HGF monoclonal antibody AMG 102 IV over 30-60 minutes on day 1. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
Tumor tissue and blood samples may be collected periodically for further laboratory analysis.
After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.
Study Design
Masking: Open Label, Primary Purpose: Treatment
Conditions
Fallopian Tube Cancer
Intervention
anti-HGF monoclonal antibody AMG 102, laboratory biomarker analysis
Status
Not yet recruiting
Source
National Cancer Institute (NCI)
Results (where available)
Links
- Source: http://clinicaltrials.gov/show/NCT01039207
- Information obtained from ClinicalTrials.gov on July 15, 2010
Published on BioPortfolio: 2014-08-27T03:17:00-0400
Clinical Trials
Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Randomized phase II trial t...
This partially randomized phase I/II trial studies the side effects and the best dose of anti-endoglin monoclonal antibody TRC105 when given together with bevacizumab and to see how well t...
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known whether giving mo...
This phase I trial studies the safety and best dose of anti-LAG-3 (anti-LAG-3 monoclonal antibody BMS-986016) or urelumab alone and in combination with nivolumab in treating patients with ...
This randomized pilot phase I trial studies the side effects and best dose of anti-SEMA4D monoclonal antibody VX15/2503 when given together with nivolumab or ipilimumab in treating patient...
PubMed Articles
Humanization of Murine Monoclonal anti-hTNF Antibody: The F10 Story.
Tumor necrosis factor (TNF) is a proinflammatory cytokine implicated in pathogenesis of multiple autoimmune and inflammatory diseases. Anti-TNF therapy has revolutionized the therapeutic paradigms of ...
The aim of this study was to provide a three-dimensional (3D) microscopic reconstruction of morphological modifications of the fallopian tube (FT) following surgical sterilization (including tuboperit...
- Nonuterine high-grade serous carcinomas (HGSCs) are believed to arise most often from precursors in the fallopian tube referred to as serous tubal intraepithelial carcinomas (STICs). A designation o...
Taking the Tube: From Normal Fallopian Tube Epithelium to Ovarian High-grade Serous Carcinoma.
Detailed pathologic studies over the past decade suggest a distal fallopian tube origin for the majority of "ovarian" high-grade serous carcinomas (HGSC). This review will summarize molecular alterati...
Patients with BRAF(V600E)-mutated metastatic colorectal cancer (mCRC) have a poorer prognosis as well as resistance to anti-EGFR antibodies. However, it is unclear whether BRAF mutations other than BR...
Medical and Biotech [MESH] Definitions
Fallopian Tube Diseases
Diseases involving the FALLOPIAN TUBES including neoplasms (FALLOPIAN TUBE NEOPLASMS); SALPINGITIS; tubo-ovarian abscess; and blockage.
Bevacizumab
An anti-VEGF recombinant monoclonal antibody consisting of humanized murine antibody. It inhibits VEGF receptors and prevents the proliferation of blood vessels.
Fluorescent Antibody Technique, Indirect
A form of fluorescent antibody technique commonly used to detect serum antibodies and immune complexes in tissues and microorganisms in specimens from patients with infectious diseases. The technique involves formation of an antigen-antibody complex which is labeled with fluorescein-conjugated anti-immunoglobulin antibody. (From Bennington, Saunders Dictionary & Encyclopedia of Laboratory Medicine and Technology, 1984)
Fallopian Tube Patency Tests
Methods for assessing the patency of the fallopian tubes.
Fallopian Tube Neoplasms
Benign or malignant neoplasms of the FALLOPIAN TUBES. They are uncommon. If they develop, they may be located in the wall or within the lumen as a growth attached to the wall by a stalk.
